Trial Profile
The purpose of this study is to evaluate the efficacy and safety of four doses of PRO-118 ophthalmic solution ophthalmic solution compared with placebo, for the treatment of seasonal (SAC) and perennial (PAC) allergic conjunctivitis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 09 Oct 2018
Price :
$35
*
At a glance
- Drugs PRO 118 (Primary)
- Indications Perennial allergic rhinitis; Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors Laboratorios Sophia
- 01 Oct 2018 Status changed to withdrawn prior to enrolment.
- 11 Apr 2014 New trial record